Accolade (ACCD) Revenue & Revenue Breakdown
Accolade Revenue Highlights
Latest Revenue (Y)
$414.29M
Latest Revenue (Q)
$110.47M
Main Segment (Y)
Access fees
Accolade Revenue by Period
Accolade Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-02-29 | $414.29M | 14.09% |
| 2023-02-28 | $363.14M | 17.13% |
| 2022-02-28 | $310.02M | 81.98% |
| 2021-02-28 | $170.36M | 28.57% |
| 2020-02-29 | $132.51M | 39.76% |
| 2019-02-28 | $94.81M | 23.41% |
| 2018-02-28 | $76.83M | - |
Accolade generated $414.29M in revenue during NA 2024, up 14.09% compared to the previous quarter, and up 436.97% compared to the same period a year ago.
Accolade Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-05-31 | $110.47M | -11.51% |
| 2024-02-29 | $124.83M | 25.62% |
| 2023-11-30 | $99.37M | 2.59% |
| 2023-08-31 | $96.86M | 3.90% |
| 2023-05-31 | $93.23M | -5.86% |
| 2023-02-28 | $99.03M | 8.88% |
| 2022-11-30 | $90.95M | 3.77% |
| 2022-08-31 | $87.64M | 2.47% |
| 2022-05-31 | $85.53M | -8.78% |
| 2022-02-28 | $93.76M | 12.35% |
| 2021-11-30 | $83.45M | 13.87% |
| 2021-08-31 | $73.29M | 23.12% |
| 2021-05-31 | $59.53M | 0.50% |
| 2021-02-28 | $59.23M | 54.07% |
| 2020-11-30 | $38.44M | 4.50% |
| 2020-08-31 | $36.79M | 2.49% |
| 2020-05-31 | $35.89M | -19.23% |
| 2020-02-29 | $44.44M | 49.88% |
| 2019-11-30 | $29.65M | 0.00% |
| 2019-08-31 | $29.65M | 3.09% |
| 2019-05-31 | $28.76M | -18.03% |
| 2019-02-28 | $35.09M | - |
Accolade generated $110.47M in revenue during Q1 2025, up -11.51% compared to the previous quarter, and up 111.55% compared to the same period a year ago.
Accolade Revenue Breakdown
Accolade Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Feb 24 | Feb 23 | Feb 22 |
|---|---|---|---|
| Health Care, Patient Service | $113.80M | - | - |
| Access fees | $300.49M | $284.14M | - |
| Utilization-based fees | - | $79.00M | - |
| Access Fees | - | - | $264.61M |
| Utilization-Based Fees | - | - | $45.41M |
Accolade's latest annual revenue breakdown by segment (product or service), as of Feb 24: Access fees (72.53%), and Health Care, Patient Service (27.47%).
Quarterly Revenue by Product
| Product/Service | May 24 | Feb 24 | Nov 23 | Feb 23 | Nov 22 | Aug 22 | May 22 |
|---|---|---|---|---|---|---|---|
| Access Fees | $76.96M | $70.82M | $67.88M | $68.13M | - | - | - |
| Health Care, Patient Service | $33.51M | $85.25M | $28.55M | - | - | - | - |
| Utilization-based fees | - | - | - | $20.85M | $20.98M | - | - |
| Access fees | - | - | - | $78.18M | $69.97M | - | - |
| Utilization-Based Fees | - | - | - | - | - | $19.77M | $17.40M |
Accolade's latest quarterly revenue breakdown by segment (product or service), as of May 24: Access Fees (69.67%), and Health Care, Patient Service (30.33%).
Accolade Revenue Breakdown by Country
Quarterly Revenue by Country
| Country | Feb 23 | Nov 22 | Aug 22 | May 22 |
|---|---|---|---|---|
| Access fees | $78.18M | $69.97M | - | - |
| Utilization-based fees | $20.85M | $20.98M | - | - |
| Access Fees | - | - | $67.88M | $68.13M |
| Utilization-Based Fees | - | - | $19.77M | $17.40M |
Accolade's latest quarterly revenue breakdown by geography, as of Feb 23: Access fees (78.95%), and Utilization-based fees (21.05%).
Accolade Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| EVH | Evolent Health | $1.96B | $647.14M |
| PRVA | Privia Health Group | $1.66B | $422.33M |
| PINC | Premier | $1.35B | $342.60M |
| CMAX | CareMax | $751.10M | $198.63M |
| ACCD | Accolade | $414.29M | $110.47M |
| PHR | Phreesia | $356.30M | $102.11M |
| CERT | Certara | $354.34M | $93.31M |
| CPSI | TruBridge | $326.65M | $82.71M |
| HCAT | Health Catalyst | $295.94M | $74.72M |
| HSTM | HealthStream | $279.06M | $71.56M |
| DH | Definitive Healthcare | $251.41M | $63.70M |
| NRC | National Research | $148.58M | $35.31M |
ACCD Revenue FAQ
What is Accolade’s yearly revenue?
Accolade's yearly revenue for 2024 was $414.29M, representing an increase of 14.09% compared to 2023. The company's yearly revenue for 2023 was $363.14M, representing an increase of 17.13% compared to 2022. ACCD's yearly revenue for 2022 was $310.02M, representing an increase of 81.98% compared to 2021.
What is Accolade’s quarterly revenue?
Accolade's quarterly revenue for Q1 2025 was $110.47M, a -11.51% decrease from the previous quarter (Q4 2024), and a 18.49% increase year-over-year (Q1 2024). The company's quarterly revenue for Q4 2024 was $124.83M, a 25.62% increase from the previous quarter (Q3 2024), and a 26.06% increase year-over-year (Q4 2023). ACCD's quarterly revenue for Q3 2024 was $99.37M, a 2.59% increase from the previous quarter (Q2 2024), and a 9.26% increase year-over-year (Q3 2023).
What is Accolade’s revenue growth rate?
Accolade's revenue growth rate for the last 3 years (2022-2024) was 33.63%, and for the last 5 years (2020-2024) was 212.66%.
What are Accolade’s revenue streams?
Accolade's revenue streams in b 24 are Health Care, Patient Service, and Access fees. Health Care, Patient Service generated $113.8M in revenue, accounting 27.47% of the company's total revenue Access fees generated $300.49M in revenue, accounting 72.53% of the company's total revenue, up 5.75% year-over-year.
What is Accolade’s main source of revenue?
For the fiscal year ending Feb 24, the largest source of revenue of Accolade was Access fees. This segment made a revenue of $300.49M, representing 72.53% of the company's total revenue.